30 closest matches · ranked by relevance
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 1719 ng·h/mL
Japanese Patients With ALS
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone — 2300 ng·h/mL
Hyperlipidemia · Hypertension · Diabetes
Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103
Pharmacogenetics
Primary: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting — 14; 13 Participants
Type 2 Diabetes Mellitus · Cardiovascular Diseases
Primary: Incidence of 3-point Major Adverse Cardiovascular Events (MACE) — 11,348; 393; 424; 296 Participants
Antidepressants Causing Adverse Effects in Therapeutic Use
Primary: Count of Participants Prescribed Antidepressant Medication — 5; 8; 5; 8 Participants
Anti-Psychotic · Management of Manifestations of Psychotic Disorders · Treatment of Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) - Chlorpromazine — 2671; 2720 pg/mL
Cardiovascular Disease
Primary: 12-Month Change in LDL Cholesterol — -1.1; -2.2 mg/dL
Feedback, Psychological · Clinical Trial · Substance Abuse
Primary: Change in Past 6 Month Non-Medical Use of Prescription Stimulant Medication Frequency — -2.04; -1.72; -1.03; -.38 Usage days — p=0.03
Multiple Myeloma
Primary: Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material — 307 Participants
Chronic Heart Failure
Primary: Medication Adherence — 91.2; 85.5 percentage of days covered
Epilepsy
Primary: Cmax - Peak Plasma Concentration — 14286.790; 18677.265; 15055.632; 14974.79 ng/mL
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone — 2165; 2209; 2073; 1955 ng·h/mL
Diabetes · Hypertension · Hypercholesterolemia
Primary: Probability of Resolution of Nonadherence Within 30 Days — .4286; .4290; .4554; .4437 Proportion of resolved NAEs within 30 — p=<0.01
Pharmacogenetic Testing
Primary: Clinical Global Impression — 4.07; 3.96 units on a scale — p=<0.05
Polypharmacy
Primary: Number of Participants With Changes in Signs and Symptoms Related to Adverse Effects of Prescribed Medicines. Clinical Gains and Benefits to Residents — 17 Participants
Depression
Primary: Adherence to Antidepressant Medication — 78.4; 61.9; 60.1; 40.2 percentage of adherence patients
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Healthy
Primary: Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72) — 248; 251; 266; 264 nmol*h/L
Diabetes Mellitus, Type 2 · Hypertension · Hyperlipidemia
Primary: Primary Effectiveness Outcome - LDL — 57.9; 54.8 percentage of time spent at goal
Platelet Aggregation · Platelet Transcriptome · Coronary Artery Disease
Primary: Difference in ADP-induced Platelet Aggregation — -5.2 Difference in ohms (Post-Pre)
Local Drug Concentration in Gastrointestinal Tract
Primary: The AUC of Mesalamine in Plasma — 40.8; 57.6; 36.8; 7.9 nM*h
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
Liver Transplant · Kidney Transplant
Primary: Tacrolimus Target Trough Level Maintenance — 38.4; 24.2 percentage of days
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
Lipid Metabolism Disorder
Primary: Number of Participants With Lipid Panel Control — 249; 192; 245; 231 participants
Adverse Drug Events · Adverse Drug Reactions · Drug Interaction Potentiation
Primary: Number of Re-hospitalizations at 30 and 60 Days — 0.38; 0.25; 0.7; 0.33 Re-hospitalizations — p=0.21
Diabetes Mellitus · Cardiovascular Diseases
Primary: Hemoglobin A1c — 7.8; 8.1 percent Hemoglobin A1c
Stable Coronary Heart Disease (CHD)
Primary: IPA on Day 1 — 27.09; 25.87; 33.34; 57.20 % IPA
Interaction, Adverse Herb-Drug · Diabetes Mellitus, Type 2
Primary: Metformin AUC — 59.6; 54.5; 57.3 mcg*hr/mL